293-VE) stimulates proliferation in HUVEC human umbilical vein endothelial cells in a dose-dependent manner (orange line) as measured by Resazurin (Catalog #
AR002). Proliferation elicited by Recombinant Human VEGF
165(10 ng/mL) is neutralized (green line) by increasing concentrations of Human Anti-Human VEGF (Bevacizumab Biosimilar) Monoclonal Antibody (Catalog # MAB9947). The ND
50 is typically 10-80 ng/mL." class="big_lightbox">

293-VE) stimulates proliferation in HUVEC human umbilical vein endothelial cells in a dose-dependent manner (orange line) as measured by Resazurin (Catalog #
AR002). Proliferation elicited by Recombinant Human VEGF
165(10 ng/mL) is neutralized (green line) by increasing concentrations of Human Anti-Human VEGF (Bevacizumab Biosimilar) Monoclonal Antibody (Catalog # MAB9947). The ND
50 is typically 10-80 ng/mL." alt="Recombinant Human VEGF
165(Catalog #
293-VE) stimulates proliferation in HUVEC human umbilical vein endothelial cells in a dose-dependent manner (orange line) as measured by Resazurin (Catalog #
AR002). Proliferation elicited by Recombinant Human VEGF
165(10 ng/mL) is neutralized (green line) by increasing concentrations of Human Anti-Human VEGF (Bevacizumab Biosimilar) Monoclonal Antibody (Catalog # MAB9947). The ND
50 is typically 10-80 ng/mL." class="big_thumb" />